BHCM
ALNY icon

Brevan Howard Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brevan Howard Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Sell
1,124
-3,497
-76% -$1.05M ﹤0.01% 1641
2026
Q1 		$1.53M Buy
4,621
+184
+4% +$62.6K 0.01% 685
2025
Q4 		$1.76M Sell
4,437
-1,733
-28% -$767K 0.02% 523
2025
Q3 		$2.81M Buy
+6,170
New +$2.51M 0.01% 426
2025
Q1 		– Sell
-1,333
Closed -$314K – 1137
2024
Q4 		$314K Buy
1,333
+44
+3% +$11.6K ﹤0.01% 758
2024
Q3 		$355K Buy
+1,289
New +$336K ﹤0.01% 790

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's ALNY Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 76% in Q2 2026, selling an estimated $1.05M and leaving 1,124 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Brevan Howard Capital Management first reported a position in ALNY in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.81M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Brevan Howard Capital Management held 1,124 shares of Alnylam Pharmaceuticals worth $338K as of Q2 2026.
  • Brevan Howard Capital Management sold 3,497 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1641 holding.
  • Brevan Howard Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Brevan Howard Capital Management's Alnylam Pharmaceuticals position peaked at $2.81M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.